PhoenixBio Co (TSE:6190) Net Margin %: 13.95% (As of Mar. 2026)

What is PhoenixBio Co Net Margin %?

PhoenixBio Co TSE:6190 -7.16% 62 Net Margin % is 13.95% as of Mar. 2026. GuruFocus rates TSE:6190 with a GF Score™ of 62/100 and a GF Value™ of 円361.16 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 946 Biotechnology companies, PhoenixBio Co ranks better than 79.39% on this metric.

Net margin is calculated as Net Income divided by its Revenue. PhoenixBio Co's Net Income for the six months ended in Mar. 2026 was 円113 Mil. PhoenixBio Co's Revenue for the six months ended in Mar. 2026 was 円809 Mil. Therefore, PhoenixBio Co's net margin for the quarter that ended in Mar. 2026 was 13.95%.

The historical rank and industry rank for PhoenixBio Co's Net Margin % or its related term are showing as below:

TSE:6190' s Net Margin % Range Over the Past 10 Years
Min: -31.71 Med: -23.85 Max: 23.23
Current: 8

TSE:6190's Net Margin % is ranked better than
79.39% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs TSE:6190: 8.00

PhoenixBio Co (TSE:6190) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

PhoenixBio Co Net Margin % Related Terms

PhoenixBio Co Net Margin % Historical Data

* Premium members only.

The historical data trend for PhoenixBio Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhoenixBio Co Net Margin % Chart

PhoenixBio Co Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Net Margin %

Get a 7-Day Free Trial

-29.28

23.23

1.54

-29.13

8.00

PhoenixBio Co Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
Net Margin %	Get a 7-Day Free Trial															-0.15	-15.83	-43.04	1.63	13.95

TSE:6190 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, PhoenixBio Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhoenixBio Co Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where PhoenixBio Co's Net Margin % falls into.

Save Embed

62GF Score

PhoenixBio Co Ltd TSE:6190

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PhoenixBio Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

PhoenixBio Co's Net Margin for the fiscal year that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (A: Mar. 2026 )	/	Revenue (A: Mar. 2026 )
	=	125.228	/	1565.532
	=	8.00 %

PhoenixBio Co's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	112.921	/	809.18
	=	13.95 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of 13.95% mean?

PhoenixBio Co (TSE:6190) has a Net Margin % of 13.95% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on PhoenixBio Co and its competitors. According to the industry distribution chart, PhoenixBio Co ranks #195 out of 946 companies in the Biotechnology industry, placing it in the top 20.6%.

Is PhoenixBio Co's Net Margin % too high?

PhoenixBio Co's current Net Margin % is 13.95%. Based on the distribution chart, PhoenixBio Co ranks #195 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PhoenixBio Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does PhoenixBio Co's Net Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #195 out of 946 companies for Net Margin %. This places PhoenixBio Co in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PhoenixBio Co and its competitors. PhoenixBio Co's current Net Margin % is 13.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PhoenixBio Co stock overvalued right now?

Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Modestly Undervalued. The stock's GF Value™ is 円361.16, compared to a current price of 円324.00 — trading 10.3% below its estimated fair value. The current Net Margin % is 13.95%. PhoenixBio Co's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Net Margin % is 13.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhoenixBio Co (TSE:6190) Overvalued in 2026?

Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued. The current stock price of 円324.00 is trading 10.3% below its estimated GF Value™ of 円361.16. GuruFocus considers PhoenixBio Co to be Modestly Undervalued.

Key valuation signals for TSE:6190:

Net Margin %: 13.95%
GF Value™: 円361.16 vs. price of 円324.00 (10.3% below fair value)
GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhoenixBio Co Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:4598 TSE:4881 TSE:130A TSE:4884 TSE:4591 TSE:2342 TSE:4576 TSE:2183 TSE:177A TSE:206A VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 3-4-1, Kagamiyama, Hiroshima Prefecture, Higashi-Hiroshima, JPN, 739-0046

Website http://www.phoenixbio.co.jp

PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.

62GF Score

Get the complete analysis for TSE:6190

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円324.00

Price

円361.16

GF Value

View TSE:6190 Analysis

See Net Margin % data for all stocks →